Loading stock data…
The Joint Corp. (JYNT)
$8.19-0.13 (-1.56%)
Market ClosedLast close Sep 8
The Joint Corp.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
The Joint Corp. in the Healthcare sector is trading at $8.19 with a market capitalization of $118M. Wall Street consensus targets $10.00 (3 analysts), implying a +22.1% move over the next 12 months. The stock is currently 23% below its 52-week high of $10.67, remaining 7.1% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. Risk note: MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +22.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15.18M↑ | $14.82M↓ | $15.17M↑ | $13.38M↑ | $13.27M |
| Gross Profit | $12.70M↑ | $12.10M↓ | $12.35M↑ | $10.72M↑ | $10.50M |
| Operating Income | -$160,564↓ | $898,995↑ | $743,895↑ | $160,915↑ | -$1.13M |
| Net Income | $653,021↓ | $1.30M↑ | $991,097↑ | $855,009↑ | $93,363 |
Peer Comparison
JNJUNHPFE
Fundamentals
The Joint Corp. operates and is a franchisor and operator of chiropractic clinics in the United States. The company provides services under the franchise agreement, including training of franchisees and staff, site selection, construction/vendor mana...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$117.67M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
59.43
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.06
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
23.96%
Volume
Today's trading volume
139,476
Recent News
Joint Corp (JYNT) Q2 2026 Earnings Call Transcript
Patient retention hit records as refranchising nears completion.
The Joint Corp. Q2 2026 Earnings Call Summary
Moby summary of The Joint Corp.'s Q2 2026 earnings call
The Joint Corp (JYNT) (Q2 2026) Earnings Call Highlights: Refranchising Nears Completion, ...
The Joint Corp (JYNT) reports a 14% revenue surge and a $1.4 million adjusted EBITDA swing, but lowers its 2026 clinic opening guidance amid a strategic portfolio reshaping.
Joint Q2 Earnings Call Highlights
Joint (NASDAQ:JYNT) reported second-quarter results that reflected progress in its shift toward a capital-light, pure-play franchisor model, while management said patient retention improved to its highest level in more than five years. Revenue increased 14% year over year to $15.2 million for the q
The Joint Corp. (JYNT) Reports Q2 Loss, Tops Revenue Estimates
The Joint (JYNT) delivered earnings and revenue surprises of -109.09% and +3.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?